Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease.
Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC; Project Phidisa Biomarkers Team. Ledwaba L, et al. Among authors: sangweni p. PLoS One. 2012;7(3):e24243. doi: 10.1371/journal.pone.0024243. Epub 2012 Mar 20. PLoS One. 2012. PMID: 22448211 Free PMC article. Clinical Trial.
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Phidisa II Writing Team for Project Phidisa; Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D. Phidisa II Writing Team for Project Phidisa, et al. J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13. J Infect Dis. 2010. PMID: 20942650 Free PMC article. Clinical Trial.
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.
Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Matchaba G, Sangweni P, Metcalf J, Pool N, Orsega S, Emery S; PHIDISA II study team. Matthews GV, et al. Among authors: sangweni p. AIDS. 2011 Sep 10;25(14):1727-35. doi: 10.1097/QAD.0b013e328349bbf3. AIDS. 2011. PMID: 21716078 Clinical Trial.
Morbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in project Phidisa.
Maduna PH, Dolan M, Kondlo L, Mabuza H, Dlamini JN, Polis M, Mnisi T, Orsega S, Maja P, Ledwaba L, Molefe T, Sangweni P, Malan L, Matchaba G, Khabo P, Grandits G, Neaton JD. Maduna PH, et al. Among authors: sangweni p. PLoS One. 2015 Apr 9;10(4):e0121843. doi: 10.1371/journal.pone.0121843. eCollection 2015. PLoS One. 2015. PMID: 25856495 Free PMC article.
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, Highbarger HC, Somaroo H, Sangweni P, Follmann DA, Pau AK; Phidisa II Study Team. Dlamini JN, et al. Among authors: sangweni p. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):304-8. doi: 10.1097/QAI.0b013e3182278c29. J Acquir Immune Defic Syndr. 2011. PMID: 21694608 Free PMC article. Clinical Trial.